Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
This IRB-approved pilot study investigated the safety of intravenous (IV) administration of BPC-157 (Body Protection Compound 157) in humans. Two participants — a 58-year-old Asian male and a 68-year-old Caucasian female, both with prior IV BPC-157 exposure — received escalating doses over two consecutive days at a private clinic in Florida. Baseline and follow-up fasting blood work and vital signs were collected across three days. The researchers measured biomarkers related to heart, liver, kidney, and thyroid function, as well as blood glucose. Both participants reportedly tolerated the infusions without any adverse side effects, and no clinically meaningful changes in the monitored biomarkers were observed. The authors conclude that IV BPC-157 appeared safe and well-tolerated in these two individuals and call for larger studies to confirm these findings. Key limitations are substantial: the study included only two participants with prior BPC-157 exposure, lacked a control group, had no blinding, involved a very short observation window (three days), and was conducted at a single private clinic. These factors severely restrict the generalizability of the findings and preclude any broad conclusions about safety or efficacy.
Why this grade: Extremely small sample (n=2), no control group, no blinding, and only a 3-day observation window provide only minimal human safety signal with very low confidence.
Background For years, the peptide Body Protection Compound 157 (BPC-157) has been used to treat partial muscle or tendon tears. Few studies on humans have been published, with none on the intravenous use of BPC-157 in humans. Objective This IRB-approved study was conducted to assess whether intravenous BPC-157 is safe in humans. Methods Baseline blood work and vital signs were obtained from 2 participants before and after each infusion. On day 1, 10 mg of BPC-157 in 250 cc of normal saline was infused over one hour. On day 2, fasting blood work was repeated, vital signs were recorded, and 20 mg of BPC-157 in 250 cc of normal saline was infused over one hour. On day 3, fasting blood work and vital signs were repeated. Patients were questioned about any side effects at each appointment. Setting This study was performed at a private clinic in Florida. Participants Two patients participated: a 58-year-old Asian male and a 68-year-old Caucasian female, each of whom had received intravenous BPC-157 before this trial. Results The infusions of BPC-157 resulted in no measurable effects on the tested biomarkers of the heart, liver, kidneys, thyroid, or blood glucose levels. The BPC-157 peptide infusion was tolerated, with no side effects reported. Conclusion Intravenous infusion of up to 20 mg of BPC-157 in 2 healthy adults showed no adverse effects and was well-tolerated. The results of this pilot study showed the safety of BPC-157 in humans. Future studies are also needed to confirm the safety of intravenous BPC-157 in humans.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.